MEDIROM HEALTHCARE TECHNOLOG (MRM)
US58510H1032 - ADR
MRM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 66 industry peers in the Diversified Consumer Services industry. MRM may be in some trouble as it scores bad on both profitability and health. MRM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year MRM was profitable.
MRM had a negative operating cash flow in the past year.
In multiple years MRM reported negative net income over the last 5 years.
MRM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.68%, MRM is in line with its industry, outperforming 56.25% of the companies in the same industry.
MRM has a Return On Equity of 54.73%. This is amongst the best in the industry. MRM outperforms 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.68% | ||
| ROE | 54.73% | ||
| ROIC | N/A |
ROA(3y)-4.44%
ROA(5y)-4.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MRM has a Profit Margin of 1.69%. This is comparable to the rest of the industry: MRM outperforms 56.25% of its industry peers.
MRM's Profit Margin has declined in the last couple of years.
MRM has a Gross Margin of 22.98%. This is amonst the worse of the industry: MRM underperforms 84.38% of its industry peers.
MRM's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 1.69% | ||
| GM | 22.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-2.63%
GM growth 3Y21.41%
GM growth 5Y-3.79%
2. Health
2.1 Basic Checks
MRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRM has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, MRM has more shares outstanding
MRM has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.71, we must say that MRM is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.71, MRM perfoms like the industry average, outperforming 46.88% of the companies in the same industry.
MRM has a Debt/Equity ratio of 6.88. This is a high value indicating a heavy dependency on external financing.
MRM has a worse Debt to Equity ratio (6.88) than 85.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.88 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.71 |
ROIC/WACCN/A
WACC4.58%
2.3 Liquidity
MRM has a Current Ratio of 0.49. This is a bad value and indicates that MRM is not financially healthy enough and could expect problems in meeting its short term obligations.
MRM has a Current ratio of 0.49. This is amonst the worse of the industry: MRM underperforms 87.50% of its industry peers.
A Quick Ratio of 0.45 indicates that MRM may have some problems paying its short term obligations.
With a Quick ratio value of 0.45, MRM is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.49 | ||
| Quick Ratio | 0.45 |
3. Growth
3.1 Past
MRM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.97%.
The Earnings Per Share has been growing by 10.09% on average over the past years. This is quite good.
Looking at the last year, MRM shows a decrease in Revenue. The Revenue has decreased by -1.81% in the last year.
MRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.74% yearly.
EPS 1Y (TTM)-17.97%
EPS 3YN/A
EPS 5Y10.09%
EPS Q2Q%58.23%
Revenue 1Y (TTM)-1.81%
Revenue growth 3Y26.9%
Revenue growth 5Y14.74%
Sales Q2Q%-5.83%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
MRM is valuated quite expensively with a Price/Earnings ratio of 27.08.
MRM's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 29.20. MRM is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.08 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)2.68
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
MRM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MEDIROM HEALTHCARE TECHNOLOG
NASDAQ:MRM (11/22/2024, 8:00:00 PM)
2.7078
-0.17 (-6.02%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap13.37M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.08 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)2.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.68% | ||
| ROE | 54.73% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 1.69% | ||
| GM | 22.98% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.88 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.49 | ||
| Quick Ratio | 0.45 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-17.97%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.81%
Revenue growth 3Y26.9%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y